Company intelligence / Profile preview

Prevail Therapeutics Inc.

New York, New York, United Statesprevailtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Prevail Therapeutics is developing gene therapies for neurodegenerative disorders. Their lead candidate PR001 (LY3884961) is in Phase 1/2a trials for Parkinson's disease with GBA1 mutations and Type 2 Gaucher disease. The PROPEL trial for Parkinson's disease is evaluating two dose cohorts with PR001 as a one-time treatment along with concomitant methylprednisolone.

Therapeutic areas: Neurology
Modalities: AAV-based gene therapiessiRNA
Industry: Biotech

Drug pipeline

3 assets

PR001

Phase 1/2

Indications: Parkinson's disease with GBA1 mutations, Neuronopathic Gaucher disease

2 more assets in the full pipeline.

Request access →

Partnerships

Encoded Therapeutics (for use of Encoded's novel regulatory elements)

Beyond the preview

Go deeper on Prevail Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prevail Therapeutics Inc..

Explore the full profile